MET receptor agonist proteins
Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
1. A fusion protein comprising a K1 a peptide domain fused to a K1 b peptide domain wherein both K1 a and K1 b peptide domains consist of a sequence at least 90% identical to SEQ ID NO: 1, wherein the domains are directly linked or linked through a linker of 1 to 20 amino acids and wherein said fusion protein induces activation of the tyrosine kinase receptor MET.
2. The fusion protein according to claim 1 , wherein said peptide domains K1 a and K1 b are identical.
3. The fusion protein according to claim 1 , wherein each of said peptide domains K1 a and K1 b consists of an amino acid sequence selected from the amino sequences SEQ ID NO: 1 and SEQ ID NO: 2.
4. The fusion protein according to claim 1 , wherein the domains are linked through a linker of 1 to 20 amino acids.
5. The fusion protein according to claim 1 , wherein the domains are linked through a linker of 10 to 20 amino acids.
6. A nucleic acid molecule encoding the fusion protein of claim 1 .
7. A composition comprising the nucleic acid molecule of claim 6 and a pharmaceutically acceptable vehicle.
8. The nucleic acid molecule of claim 6 consisting of the nucleic acid sequence SEQ ID NO: 10.
9. An expression vector containing a nucleic acid molecule of claim 6 .
10. A composition comprising the expression vector of claim 9 and a pharmaceutically acceptable vehicle.
11. The expression vector of claim 9 comprising or consisting of SEQ ID NO: 11.
12. An host cell containing the expression vector as claimed in claim 9 , wherein the host cell is selected from the group consisting of yeast cells and bacterial cells.
13. A composition comprising the host cell of claim 12 and a pharmaceutically acceptable vehicle.
14. A method for producing a fusion polypeptide comprising culturing the host cell of claim 12 under conditions suitable for expression followed by extracting and purifying the fusion protein.
15. A composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable vehicle.
16. A fusion protein comprising or consisting of an amino acid sequence SEQ ID NO: 7 or an amino acid sequence with at least 90% identity to SEQ ID NO: 7.